1Mitchison HC, Palmer JM, et al. A controlled trial of prednisolone treatment in primary, biliary cirrhosis: three-year results, J Hepatol, 1992,15:336-44.
2Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial.Gastroenterology, 1993,104 : 519-26.
3Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology, 1991,101 : 1332-1338
4Kaplan M, Schmid C, McKusick A. et al. Double-blind trial of methotrexate (MTX) versus colchicine (COLCH) in primary biliary cirrhosis ( PBC). Hepatology, 1993,18(Suppl) : 176A.
5Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol. 2001.35: 134-146.
6Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatie liver disease: mechanisms of action and therapeutic: use revisited. Hepatology,1993,18 ( Suppl ) : 176A.
7Lindor KD, Dickson ER, Jorgensen RA, et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology, 1995, 22:1158-1162.
8Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol, 2001, 35:134-146.
9Paumgarther G, Beuers U. Ursordeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology,2002, 36 : 525-531.
10Beuers U, Spengler U, Zwiebel FM, et al. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology, 1992, 15:603-608.
